AMGN vs MRNA: stock comparison and AI forecast
Amgen Inc (AMGN) and Moderna, Inc. (MRNA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AMGN Amgen Inc
- Price
- $461.26 +39.9% · 6M
- Market Cap
- $249.37B
- P/E Ratio
- 28.7x
- Size
- mega-cap
- AI Forecast
MRNA Moderna, Inc.
- Price
- $228.44 +389.1% · 6M
- Market Cap
- $91.20B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- AMGN is 2.7 times larger than MRNA by market capitalization ($249.37B against $91.20B).
- Over the last six months MRNA returned +389.1% and AMGN +39.9%.
- AMGN turns 22.9% of its revenue into net income, against -141.4% for MRNA.
- AMGN carries 7.18 times debt per unit of equity, against 0.62 times for MRNA.
- AMGN yields 2.12% in dividends; MRNA pays none.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AMGN | MRNA |
|---|---|---|
| Market Cap | $249.37B | $91.20B |
| P/E Ratio | 28.67x | – |
| P/B Ratio | 21.34x | 13.49x |
| Dividend Yield | 2.12% | – |
| EPS | $16.09 | $-7.98 |
| Book Value/Share | $21.62 | $16.93 |
| Revenue/Share | $70.46 | $5.58 |
| FCF/Share | $18.82 | $-3.12 |
Profitability & Margins
| Metric | AMGN | MRNA |
|---|---|---|
| ROE | 74.8% | -46.6% |
| ROA | 9.1% | -28.8% |
| ROIC | 16.3% | -39.4% |
| Gross Margin | 69.5% | 23.4% |
| Operating Margin | 30.0% | -149.0% |
| Net Margin | 22.9% | -141.4% |
| EBT Margin | 27.0% | -138.6% |
| Tax Rate | 15.0% | -2.1% |
Financial Health
| Metric | AMGN | MRNA |
|---|---|---|
| Current Ratio | 1.37x | 2.29x |
| Quick Ratio | 1.13x | 2.18x |
| D/E Ratio | 7.18x | 0.62x |
| Financial Leverage | 8.18x | 1.62x |
| Interest Coverage | 5.2x | -85.7x |
| Working Capital | $9.46B | $3.28B |
Cash Flow
| Metric | AMGN | MRNA |
|---|---|---|
| Operating Cash Flow | $12.48B | -$1.07B |
| Free Cash Flow | $10.18B | -$1.24B |
| Capital Spending | -$2.30B | -$171M |
| OCF Growth YoY | 3.9% | – |
| FCF Growth YoY | -4.0% | – |
| FCF/Sales | 26.7% | -55.8% |
| CapEx/Sales | 6.0% | 7.7% |
Operational Efficiency
| Metric | AMGN | MRNA |
|---|---|---|
| Asset Turnover | 0.40x | 0.20x |
| Receivables Turnover | 3.7x | 131.1x |
| Inventory Turnover | 1.9x | 6.1x |
| Fixed Assets Turnover | 4.5x | 1.1x |
| Days Sales Outstanding | 98 days | 3 days |
| Days Inventory | 196 days | 60 days |
| Payables Period | 90 days | 36 days |
| Cash Conversion Cycle | 203 days | 27 days |
Income Statement
| Metric | AMGN | MRNA |
|---|---|---|
| Total Revenue | $38.09B | $2.23B |
| Operating Income | $11.43B | -$3.32B |
| Net Income | $8.74B | -$3.15B |
| R&D Expense | $7.63B | $2.88B |
| SG&A Expense | $7.02B | – |
| Cost of Goods Sold | $11.61B | $1.71B |
Dividend & Shareholder Information
| Metric | AMGN | MRNA |
|---|---|---|
| Dividends Per Share | $9.78 | – |
| Payout Ratio | 60.8% | – |
| Shares Outstanding | 541M | 399M |
| Net Income Growth | 32.1% | – |
| EPS Growth | 33.8% | – |
AMGN vs MRNA: stock comparison and AI forecast
Which is bigger, AMGN or MRNA?
AMGN is 2.7 times larger than MRNA by market capitalization ($249.37B against $91.20B).
Which stock performed better over the last six months, AMGN or MRNA?
Over the last six months MRNA returned +389.1% and AMGN +39.9%.
Which one does Intratio's AI model rank higher, AMGN or MRNA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.